title: Antibodies against human IFN-alpha and -beta recognized the immunosuppressive domain of HIV-1 gp41 and inhibit gp41-binding to the putative cellular receptor protein p45.
abstract: Sequence-comparison indicates existing sequence-similarity between receptor-binding regions of human type 1 IFNs (IFN-alpha, -beta and -omega) and HIV-1 gp41. Previous findings had suggested that the increased levels of antibodies against human IFN-alpha and -beta in HIV-1-infected individuals are associated with a common epitope on gp41, IFN-alpha and -beta. To clarify the relationship between human type I interferon and HIV-1 gp41 and the protective mechanism of an IFN-alpha-vaccine, we prepared antisera against human IFN-alpha, -beta and HIV-1 gp41, and examined crossreaction of these antisera and their inhibition of gp41 binding to its binding protein p45. Mouse antisera against IFN-alpha and -beta could recognize HIV-1 recombinant soluble (aa539-684) and gp41 immunosuppressive peptide (ISP, aa583-599), while normal mouse sera (pre-immune sera) did not. Mouse antisera to rsgp41 crossreacted with IFN-alpha and -beta. Besides, mouse antisera to IFN-alpha and beta, like mouse anti-rsgp41 antiserum, could inhibit gp41-binding to its putative cellular receptor protein p45, while normal mouse serum did not. These results indicate that antibodies crossreacting with gp41 ISP, IFN-alpha and -beta, could be induced by this common immunological epitope in vivo.
authors.affiliation: Department of Biological Science and Biotechnology, Tsinghua University, Beijing, PR China. chenyh@mail.tsinghua.edu.cn
authors.forename: Y H
authors.initials: YH
authors.lastname: Chen
authors.forename: W
authors.initials: W
authors.lastname: Wu
authors.forename: J
authors.initials: J
authors.lastname: Yang
authors.forename: S F
authors.initials: SF
authors.lastname: Sui
authors.forename: J
authors.initials: J
authors.lastname: Sun
authors.forename: M P
authors.initials: MP
authors.lastname: Dierich
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D000918:Antibody Specificity; D003429:Cross Reactions; D015483:HIV Antibodies / Q000276:immunology* / Q000494:pharmacology; D015700:HIV Envelope Protein gp41 / Q000737:chemistry / Q000276:immunology*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D007370:Interferon Type I / Q000276:immunology; D016898:Interferon-alpha / Q000276:immunology*; D016899:Interferon-beta / Q000276:immunology*; D051379:Mice; D008969:Molecular Sequence Data; D010446:Peptide Fragments / Q000378:metabolism; D011485:Protein Binding / Q000187:drug effects; D011991:Receptors, Virus / Q000378:metabolism*; D011994:Recombinant Proteins; D020349:Surface Plasmon Resonance
chemical_list: D015483:HIV Antibodies; D015700:HIV Envelope Protein gp41; D007370:Interferon Type I; D016898:Interferon-alpha; D010446:Peptide Fragments; D011991:Receptors, Virus; D011994:Recombinant Proteins; D016899:Interferon-beta